Lisata Therapeutics, Inc. (LSTA)

Over the past six months, Lisata Therapeutics, Inc.'s stock price has been impacted by several events. The Q3 2025 earnings report showed an EPS beat but a stock decline due to cash burn concerns. Q2 2025 financial results indicated a net loss improvement and revenue from a license fee with Catalent, Inc. Lisata Therapeutics entered into a term sheet to be acquired by Kuva Labs for $4.00 per share. The license agreement with Qilu Pharmaceutical for certepetide was mutually terminated. LSTA stock has shown significant volatility, increasing by 77.07% over the last six months, with a stock price of $4.11 per share as of January 23, 2026.

Lisata Therapeutics, Inc. does not experience traditional demand seasonality for its products and services. The demand for its investigational drugs is driven by the progression of clinical trials, regulatory approvals, and the unmet medical needs of patient populations. The company's revenue is currently modest, primarily from license agreements, and its focus is on advancing its pipeline through clinical development.

Lisata Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies for patients with unmet medical needs, primarily in oncology. The company operates within the Healthcare sector and the Biotechnology industry, leveraging its CendR Platform® Technology to enable targeted delivery of therapeutic agents directly to diseased tissues. Its lead investigational product candidate is certepetide (LSTA1), designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to selectively target and penetrate solid tumors more effectively. Certepetide has received several designations, including Orphan Drug Designation for pancreatic cancer in the U.S. and Europe, as well as for glioblastoma multiforme and osteosarcoma in the U.S. Lisata also has clinical development programs based on its autologous CD34+ cell therapy technology platform, targeting diseases such as critical limb ischemia, coronary microvascular dysfunction (XOWNA®), and diabetic kidney disease (LSTA201).

Lisata Therapeutics, Inc. is headquartered in Basking Ridge, New Jersey, United States. The company's clinical trials for certepetide include Estonia, Latvia, and are planned to expand into Lithuania.

Lisata Therapeutics' brand reputation has been influenced by positive clinical advancements and financial considerations. The company received a "Strong Buy" consensus rating from analysts, but other analyst ratings indicate a "Hold" consensus. Positive events include promising advancements with certepetide, a BioTech Breakthrough Award, and regulatory designations. Challenges include funding uncertainty and stock price reaction to earnings.

As of Q4 2025, 42 institutions hold shares of Lisata Therapeutics Inc., with a combined market value of approximately $740.21K, accounting for 8.39% of the total shares. Major institutional owners include Vanguard Group Inc., Renaissance Technologies Llc, and BlackRock, Inc. Lisata Therapeutics is owned by 994.21% Lisata Therapeutics insiders. Rimasia Capital Partners Manager Ltd is the largest individual shareholder, owning 24.63 million shares, representing 279.26% of the company.